Skip to content

Screening for Neurodevelopmental Disorders in Siblings of Children With Autism Diagnosed in Tertiary Centers

Screening for Neurodevelopmental Disorders in Siblings of Children With Autism Diagnosed in Tertiary Centers

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05512637
Acronym
FRATSA
Enrollment
384
Registered
2022-08-23
Start date
2023-11-28
Completion date
2026-11-30
Last updated
2025-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism Spectrum Disorder, Neurodevelopmental Disorders, Siblings

Keywords

Siblings, Screening, Autism Spectrum Disorder, Neurodevelopmental Disorders

Brief summary

In this study, a selective and multi-stages screening for neurodevelopmental disorders (NDD) in siblings of children with a confirmed ASD is done. The main aims are to estimate the prevalence of NDD among siblings and to evaluate the feasibility and acceptability of a standardized screening procedure.

Detailed description

Although NDD are frequent among siblings of children with ASD, their developmental screening is not yet sufficiently organized in routine practice. The needs and the characteristics of these siblings have yet to be better understood in order to define their developmental surveillance.

Interventions

DIAGNOSTIC_TESTStep 1 - Screening ; Step 2 - Clinical interview

Step 1: screening is performed by online parental questionnaires (SRS-2, Identidys scale, DCDQ, parental concerns questionnaire ) via a web platform. Parents and registered doctors will be informed by mail in case of negative screening; In case of positive screening, they will be called by phone in order to give them the results and to invite them for a clinical and semi-structured interview. Step 2: The semi-structured interview will be performed by a psychologist specialized in NDD in order to clinically confirm the results of the screening and refer the child to care and interventions, by mail to the registered doctor. Around 12 months after this interview, parents will be called by phone to collect a description of the referral and their satisfaction about the screening process.

Sponsors

Direction Générale de l'Offre de Soins
CollaboratorOTHER_GOV
University Hospital, Montpellier
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
2 Years to 16 Years
Healthy volunteers
No

Inclusion criteria

* Step 1: Brothers or sisters (including stepsisters and brothers); aged between 2 and 16 years; living in Occitanie; informed and express consent of parents ; affiliated to social security. * Step 2: step 1 positive screening or parental concerns for child's development ; parental signed informed consent.

Exclusion criteria

* Parents (or child) refusal to participate; adopted brother or sister. Do not speak French

Design outcomes

Primary

MeasureTime frameDescription
Percentage of family participation12 monthsFamilies' participation rate and, among participants, number of children with a NDD diagnosis at the end of the screening study.

Secondary

MeasureTime frameDescription
Sensibility, specificity, positive predictive values (PPV) and negative predictive values (NPV) of the screening procedure12 months
Percentage of satisfied parents12 monthsEstimate the level of satisfaction of parents who participated in the screening with the parental satisfaction score via the Visual Analog Scale (VAS). VAS is a scale from 0 (not at all satisfied) to 100 (very satisfied)

Countries

France

Contacts

Primary ContactCécile MICHELON
c-michelon@chu-montpellier.fr467330986
Backup ContactCharlotte GERBE
charlotte.gerbe@chu-montpellier.fr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026